Endevica Bio drug candidate shows success in weight loss in new study
NORTHBROOK, Ill., April 23, 2024 - Endevica Bio, a company developing first-in-class peptide drug candidates, announced its novel weight-loss treatment was successful in a recent diet-induced obesity (DIO) rat study.
This latest research solidifies... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 23, 2024 Category: Pharmaceuticals Source Type: clinical trials
FDA Approves Clinical Trial for GFH925 Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
SHANGHAI, April 19, 2024. GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Doctors Underutilize Next-Gen Antibiotics to Fight Resistant Infections in U.S. Hospitals
April 19, 2024 -- Despite Food and Drug Administration (FDA)-approval of seven next-generation antibiotics to fight infections caused by resistant“gram-negative” bacteria, clinicians frequently continue to treat antibiotic-resistant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024– Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
NIH Researchers Develop AI Tool with Potential to More Precisely Match Cancer Drugs to Patients
April 18, 2024 -- In a proof-of-concept study, researchers at the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses data from individual cells inside tumors to predict whether a person’s cancer... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
BOSTON--(BUSINESS WIRE)--Apr. 18, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
BiVictriX Announces FDA Orphan Drug Designation and Completion of FDA INTERACT Meeting for BVX001 in the Treatment of Acute Myeloid Leukemia
Alderley Park, 17 April 2024– BiVictriX Therapeutics plc (AIM: BVX), a biotechnology company developing novel, next-generation bispecific Antibody Drug Conjugates (bxADCs) which are designed to offer substantially improved cancer cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
EAGLE-1 Phase III Data Show Potential for Gepotidacin as a New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea (GC) Amid Growing Resistance to Existing Treatments
17 April 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator SP-624
MORRISVILLE, N.C.--(BUSINESS WIRE) April 16, 2024 -- Arrivo BioVentures announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.
This... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
TLX101-CDx (Pixclara) Granted FDA Fast Track Designation
Melbourne (Australia) | 16 April 2024 -- Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
CLEVELAND, April 15, 2024 (GLOBE NEWSWIRE) -- NovelMed today announced that the Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 15, 2024 Category: Pharmaceuticals Source Type: clinical trials
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
TARRYTOWN, New York, April 11, 2024– via IBN– PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
Study Reveals No Causal Link Between Neurodevelopmental Disorders and Acetaminophen Exposure Before Birth
April 11, 2024 -- Study reveals no causal link between neurodevelopmental disorders and acetaminophen exposure before birth. NIH-funded research in siblings finds previously reported connection is likely due to other underlying... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
OCALA, Fla., April 10, 2024— AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 10, 2024 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the“Company”) today announced interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
